Epstein vs. Epstein: Drug Price Subsidies

If you're planning a discussion at the University of Chicago Law School and you want a very lively debate, you ask Richard Epstein to be one of your panelists. So how could we go wrong for a Loop Luncheon on Reunion weekend by asking Richard to debate himself? On May 4 he did exactly that. The event was billed as Epstein vs. Epstein, and the topic was "Why should the U.S. subsidize the world with our high prescription drug prices?" Professor Epstein served as moderator as well, of course. If you'd like to hear the results, you can listen here.

Comments

[Joan A. Conway]

Big Science has gone by the wayside, generally speaking from where it once was.

However, the development of new perscription drugs is finding cures or theraputic maintenance for some of our great aches and pains.

So that Arthritis find hope in drugs that enable them to fight progressive joint damage, etc.

When there is a market for over 30 million people, who take NSAID, including many who rely on the drug to reduce the pain and/or inflammation caused by arithritis, of which there are more than 20 commercially available NSAIDs available for the sufferers, and more than 100,000 Americans are hospitalized and more than 16,500 die as a result of GI problems related to the use of NSAIDs, subsidizing these drugs is big business with lobby fees attached to it and political contributions.